Prostate Cancer Clinical Trial
— ARNEOOfficial title:
Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled Trial
RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy without a survival benefit. There is no evidence yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this setting. Thus novel studies are needed to assess this treatment combination. PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer patients.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | December 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial 2. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations 3. Male aged 18 years or older (within 80 years) 4. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features 5. Diagnosis of intermediate (at least 2 of the following factors: cT2b, biopsy GS 7, PSA 10-20ng/ml) or high-risk prostatic adenocarcinoma (clinical stage=T2c and/or biopsy GS=8 and/or PSA>20ng/ml), cN0-cN1, cM0. 6. Patient amenable for open or robotic radical prostatectomy + pelvic lymph node dissection 7. ECOG performance status: 0-1 8. Adequate organ function as defined by the following criteria: - White blood cells (WBC) = 4.0 x109/L - Platelet count = 100 x109/L - Hemoglobin =9 g/dl - Creatinine = 2 x ULN - Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) = 2.5 x upper limit of normality (ULN) - Total serum bilirubin =1.5 x ULN. Exclusion Criteria: 1. Previous surgical/endoscopic treatments for prostatic disease 2. Herbal and non-herbal products that in the opinion of the investigator may decrease PSA levels 3. cM1 disease 4. Any contraindication for PET or MR investigations 5. History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy) 6. Medications known to lower the seizure threshold 7. History of: - Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer currently in complete remission) within 5 years prior to randomization - Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization - Uncontrolled hypertension (systolic blood pressure =160 mmHg or diastolic BP =100 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment. - Gastrointestinal disorder affecting absorption 8. Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures. |
Country | Name | City | State |
---|---|---|---|
Belgium | University Hospitals Leuven | Leuven | Vlaams-brabant |
Lead Sponsor | Collaborator |
---|---|
Universitaire Ziekenhuizen Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Minimal Residual Disease (MRD) | Proportions of MRD between arms. MRD: tumor volume = 0.25 cm3 | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Difference in proportions of pathological downstage | Any decrease in T stage from clinical to pathological stage | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Complete pathological response rates | Difference in proportions of complete pathological response (no evidence of tumour in the postoperative specimen) between arms. | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Difference in proportions of patients with pN1 disease. | Difference in proportions of lymph node invasion between arms | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Proteins expression in prostatic tumour TMA's (tissue microarrays) | Intensity of immunoreactivity and percentage of immunoreactive cells for, selected markers between arms. The TMA's will be produced from the formalin-fixed paraffin-embedded (FFPE) specimen of the RP. | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Transcriptome analysis by microarray expression platform | To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens: clinical-grade high-density oligonucleotide microarray expression platform and cloud-based informatics pipeline to interrogate 1.4M probe sets representing all known ~46K genes and non-coding RNAs. | At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Pathway profiling and Gene Set Enrichment Analyses | To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens. Pathway profiling and Gene Set Enrichment Analyses will also be used to generate pathway scores for the 'androgen receptor signaling pathway'; determination of pathway scores for the DNA damage checkpoints and the different DNA repair pathways. | At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Genomic subtyping by exome-sequencing | Genomic subtyping (e.g., ERG, SPINK1, SPOP, FOXA1, PTEN, circulating nucleic acids (CNA) data...) will be performed based on exome-sequencing data. The exome and CNA data will be linked with the transcriptome data on androgen regulation and DNA repair pathways. | At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | PSA kinetics | Changes of PSA during time and comparison of PSA values and changes between arms. | Up to 40 months | |
Secondary | Testosterone kinetics | Comparison of total and free serum testosterone and testosterone change between arms | Up to 40 months | |
Secondary | PSA nadir </=0.3ng/ml after neoadjuvant treatment | Differences in proportions of PSA nadir =0.3ng/ml after neoadjuvant treatment.
PSA nadir after neoadjuvant therapy and before external beam radiotherapy (EBRT) is an important biomarker of hormonal response and an independent prognostic factor of prostate cancer survival. |
After 12 weeks of neoadjuvant therapy before RP + PLND | |
Secondary | Peri-operative features | Differences in peri-operative features (operative time, blood loss, grade of surgical difficulty...) will be collected to evaluate the possible effect of treatment on surgical intervention. | up to (about) 5 hours | |
Secondary | Differences in proportions of surgical complications between arms | Clavien-Dindo classification will be implemented to assess differences in surgical complications between the two arms. | Up to 6 weeks post RP + PLND | |
Secondary | Continence | Assessment of continence rates through validated preoperative and postoperative questionnaire (ICIQ) | Up to 40 months | |
Secondary | Quality of life | Assessment of Quality of life through validated preoperative and postoperative questionnaire (EORTC QLQ-C30) | Up to 40 months | |
Secondary | Erection state | Assessment of erection state through validated preoperative and postoperative questionnaire (IEEF5) | Up to 40 months | |
Secondary | Survival | Three years biochemical recurrence free survival | Up to 36 months | |
Secondary | Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR per arm | Standardized Uptake Value (SUV) change (delta) per arm comparing SUV values before and after treatment | At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR between arms | SUV delta between the two arms. | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR and tumour volume | Correlation between SUV values and the tumour volume (TV) in the RP correspondent volume of interest (VOI) at definitive pathology | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Standardized Uptake Value (SUV) on prostate [68]Ga PSMA PET/MR and Immunohistochemistry | Correlation between SUV values and PSMA expression at Immunohistochemistry | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Magnetic resonance (MR) and tumor volume (TV) per arm | Change of magnetic resonance (MR) tumor volume (TV): Tumor volume (TV) change (delta) per arm comparing TV values before and after treatment | At baseline and after12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Magnetic resonance (MR) and tumor volume (TV) between arms | Change of magnetic resonance (MR) tumor volume (TV):TV deltas between the two arms. | At baseline and after12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | PI-RADS between arms at MR | Proportion of PI-RADS between arms | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | PI-RADS score and Gleason score | Correlation between PI-RADS score and pathology Gleason score | After 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Down-staging at imaging | Proportion of down-staging | At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND | |
Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Frequencies of adverse events (AE), severe adverse events (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR) | From patient inclusion until RP + PLND |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |